Pfizer Inc
PFE
NYSE
Pharmaceuticals
$27.79
USD
-0.45 (-1.59%)
At close: Aug 20, 2026, 4:00 PM EDT
Market Cap $152.49B
Volume 29.2M
Revenue
$60.76B
TTM
-9.0%
YoY
Gross Margin
74%
TTM
+3.8%
YoY
Net Income
$3.79B
TTM
-66.7%
YoY
Operating Cash Flow
$11.13B
TTM
-36.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q3 2025 | Q1 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 16,654.0 | 13,715.0 | 17,557.0 | 14,450.0 | 15,034.0 |
YoY Growth | -5.9% | -7.8% | -1.2% | +5.4% | +2.6% |
Cost of Revenue | 4,172.0 | 2,845.0 | 5,272.0 | 3,548.0 | 4,092.0 |
Gross Profit | 12,482.0 | 10,870.0 | 12,285.0 | 10,902.0 | 10,942.0 |
Selling, General & Administrative | 3,186.0 | 3,031.0 | 4,162.0 | 2,961.0 | 3,411.0 |
Other Operating Expenses | 1,676.0 | 687.0 | 817.0 | 237.0 | 473.0 |
Total Operating Expenses | 8,631.0 | 7,132.0 | 9,415.0 | 6,871.0 | 7,878.0 |
Operating Income | 3,851.0 | 3,738.0 | 2,870.0 | 4,031.0 | 3,064.0 |
EBITDA | 7,189.0 | 6,043.0 | 5,374.0 | 5,881.0 | 5,159.0 |
Other Income / Expense | -517.0 | -953.0 | -4,512.0 | -861.0 | -3,163.0 |
Total Other Income / Expense | -517.0 | -953.0 | -4,512.0 | -861.0 | -3,717.0 |
Income Before Income Taxes | 3,334.0 | 2,785.0 | -1,642.0 | 3,170.0 | -653.0 |
Income Taxes | -216.0 | -189.0 | -2.0 | 461.0 | -407.0 |
Net Income | 3,551.0 | 2,973.0 | -1,640.0 | 2,696.0 | -238.0 |
Consolidated Net Income / Loss | 3,550.0 | 2,974.0 | -1,640.0 | 2,696.0 | -238.0 |
Net Income Attributable to Common Shareholders | 3,541.0 | 2,967.0 | -1,648.0 | 2,687.0 | -248.0 |
Basic EPS | $0.62 | $0.52 | -$0.29 | $0.47 | -$0.04 |
Diluted EPS | $0.62 | $0.52 | -$0.29 | $0.47 | -$0.04 |
Basic Shares Outstanding | 5,685.0M | 5,675.0M | 5,687.0M | 5,691.0M | 5,699.0M |
Diluted Shares Outstanding | 5,714.0M | 5,710.0M | 5,722.0M | 5,731.0M | 5,699.0M |